

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Propafenone 150 mg Tablet (DIN 02243324) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 17, 2016**.

PROPAFENONE HCL

150 MG TABLET

| | | | |
|-------------|-----------------|-----|-----------|
| 00002243324 | APO-PROPAFENONE | APX | \$ 0.2965 |
| 00000603708 | RYTHMOL | BGP | \$ 1.2012 |

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage of Methotrexate (Preserved) 25 mg/ml Injection USP (DIN 02398427) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 18, 2016**.

METHOTREXATE SODIUM

25 MG / ML (BASE) INJECTION

| | | | |
|-------------|---------------------------------|-----|-----------|
| 00002398427 | METHOTREXATE (PRESERVED) | SDZ | \$ 4.4600 |
| 00002182777 | METHOTREXATE SODIUM (PRESERVED) | HSP | \$ 8.4472 |

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Novo-Clobazam 10 mg Tablet (DIN 02238334) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 21, 2016**.

CLOBAZAM

10 MG TABLET

| | | | |
|-------------|---------------|-----|-----------|
| 00002238334 | NOVO-CLOBAZAM | TEV | \$ 0.1152 |
| 00002244638 | APO-CLOBAZAM | APX | \$ 0.2197 |

... continued from previous page

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Novo-Clobazam 10 mg Tablet (DIN 02238334) manufactured by Teva Canada Limited and Apo-Clobazam 10 mg Tablet (DIN 02244638) manufactured by Apotex Inc., Frisium 10 mg Tablet (DIN 02221799), manufactured by Lundbeck Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Teva Canada Limited and Apotex Inc. have advised Alberta Blue Cross that the shortages of Novo-Clobazam 10 mg Tablet (DIN 02238334) and Apo-Clobazam 10 mg Tablet (DIN 02244638) respectively have been resolved.

As a result, Frisium 10 mg Tablet (DIN 02221799) will no longer be considered a temporary benefit for the *ADBL* after **November 18, 2016**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)
FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.642 2016/10

